Morning Pinch My software must be having a moment ,, can you...

Thank you for posting what a great read.
Rounding It
Out Syntara differentiates itself from competitors through its unique mechanistic approach – targeting extracellular matrix dysfunction and fibrosis – where others focus on symptomatic relief or narrower pathways. This is a critical edge in crowded markets like MF, where JAK inhibitors dominate but leave 75% of patients without long-term solutions, or MDS, where hypomethylating agents offer transient benefits. The company’s ability to secure government grants and regulatory incentives, such as the seven-year market exclusivity tied to Orphan Drug status, enhances its commercial viability and attractiveness to investors seeking de-risked opportunities. Its seasoned leadership, including CEO Gary Phillips with over 30 years in biotech, further instils confidence in its ability to execute on Phase 3 trials, secure approvals, and drive partnerships or acquisitions. For investors, Syntara represents a rare blend of scientific innovation, market opportunity, and operational excellence, poised to deliver significant returns as it transitions from clinical promise to commercial reality.

Could do with a UK Parkinson Trial Update..
To maintain strategic focus, we anticipate the Company will pursue out-licensing agreements for SNT-4728 and SNT-6302 upon completion of their respective Phase 2 trials. This approach would allow the company to concentrate its resources on the more clinically advanced SNT-5505 program while leveraging external partners to drive the development and commercialisation of its other assets

Morning Pinch
My software must be having a moment ,, can you give me a timeframe when the 4m @ 6c trades went through?
cheers

I see the 3m block @6.6c at 11;25


Hoping to see a climb to 7c today .. still no media or awareness from the Company??